On Tuesday, Zevra Therapeutics Inc (NASDAQ: ZVRA) was -3.37% drop from the session before settling in for the closing price of $8.91. A 52-week range for ZVRA has been $4.20 – $9.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 42.16% over the last five years. When this article was written, the company’s average yearly earnings per share was at 90.90%. With a float of $54.08 million, this company’s outstanding shares have now reached $54.68 million.
The firm has a total of 59 workers. Let’s measure their productivity. In terms of profitability, gross margin is 78.84%, operating margin of -177.09%, and the pretax margin is -185.68%.
Zevra Therapeutics Inc (ZVRA) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Zevra Therapeutics Inc stocks. The insider ownership of Zevra Therapeutics Inc is 1.10%, while institutional ownership is 65.38%. The most recent insider transaction that took place on Mar 28 ’25, was worth 2,352. In this transaction Director of this company bought 300 shares at a rate of $7.84, taking the stock ownership to the 1,800 shares. Before that another transaction happened on Mar 19 ’25, when Company’s Director bought 10,000 for $7.96, making the entire transaction worth $79,624. This insider now owns 40,000 shares in total.
Zevra Therapeutics Inc (ZVRA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 90.90% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
You can see what Zevra Therapeutics Inc (ZVRA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.89, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.73 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Analysing the last 5-days average volume posted by the [Zevra Therapeutics Inc, ZVRA], we can find that recorded value of 1.04 million was better than the volume posted last year of 0.48 million. As of the previous 9 days, the stock’s Stochastic %D was 92.19%. Additionally, its Average True Range was 0.42.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 87.68%, which indicates a significant increase from 82.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.91% in the past 14 days, which was higher than the 47.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.64, while its 200-day Moving Average is $7.93. Now, the first resistance to watch is $8.82. This is followed by the second major resistance level at $9.04. The third major resistance level sits at $9.16. If the price goes on to break the first support level at $8.48, it is likely to go to the next support level at $8.36. Should the price break the second support level, the third support level stands at $8.14.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
There are 54,680K outstanding shares of the company, which has a market capitalization of 470.80 million. As of now, sales total 23,610 K while income totals -105,510 K. Its latest quarter income was 20,400 K while its last quarter net income were -3,100 K.
